127
Participants
Start Date
August 4, 2010
Primary Completion Date
December 12, 2016
Study Completion Date
December 12, 2016
MART-1
THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. MART-1:26-35(27L) peptide vaccine
NY-ESO-1
NY-ESO-1 peptide vaccine
gp100:209-217(210M)
THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. gp100:209-217(210M) peptide vaccine
gp100:280-288(288V)
gp100:280-288(288V) peptide vaccine
Montanide ISA 51 VG
Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.
BMS-936558
BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen \[HLA\] unrestricted)
H. Lee Moffitt Cancer Center and Research Institute, Tampa
Collaborators (2)
National Cancer Institute (NCI)
NIH
Bristol-Myers Squibb
INDUSTRY
Medarex
INDUSTRY
H. Lee Moffitt Cancer Center and Research Institute
OTHER